Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors

PCSK9 Inhibitors Show Similar Efficacy in Diabetics as in Other High-Risk Groups

SPRINT Trial: Mortality Benefit Associated with Intensive Blood Pressure Control

One Size Does Not Fit All in the Treatment of Asthma

Debating North American Cholesterol Guidelines and the Role of PCSK9 Inhibitors

TKI Targeted at T790M Lung Cancer Mutations Yields High Rate of Disease Control

Concrete Steps Taken to Base Severe Asthma Treatment on Molecular Rather than Clinical Phenotypes

PCSK9 Inhibitor Achieves Persistent LDL-C Control and Sustained Safety in a Challenging Population

Interleukin-6 Inhibitors: Improving Biologic Specificity in the Control of Rheumatoid Arthritis

Emerging Outcomes Data with PCSK9 Inhibitors Show Cardiovascular Risk Reductions in Line with LDL Control